Skip to NavigationSkip to content

kidney disease

NICE does not recommend cancer drug combination to the NHS

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma in adults (RCC).

The evidence from treating kidney cancer patients with pembrolizumab (Keytruda) and axitinib (Inlyta) showed promise, but NICE were concerned about its long-term benefit. Its clinical and cost-effectiveness estimates were also above what NICE would normally consider as an acceptable use of NHS resources. 

Top Ten most popular articles on this week!

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK announced redundancies as Janssen scored twice in Phase 3 trials in chronic kidney disease and HIV.

Baxter partners up with Mayo Clinic for new "centre of exellence" in renal care

American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a bid to establish a “renal care centre of excellence” in the US.

The partnership marks the first launch of an initiative from the five-year Baxter and Mayo Clinic agreement signed in 2017 to drive innovation in areas of unmet need. The new centre will be based in Jacksonville, Florida at the Mayo Clinic Dialysis Center, a site which promises “state-of-the-art dialysis services in a comfortable, home-like facility”

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy of its SGLT2 inhibitor Invokana (canagliflozin), but not because it had proved ineffective.

On the contrary, after the drug met its pre-specified efficacy criteria in the prevention of clinically important renal and cardiovadcvular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the company deemed it pertinent to close the study early.

SMC approves first ever treatment for genetic kidney disease


The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic kidney disease (ADPKD). 

Jinarc (tolvaptan) is the first medicine to treat the underlying cause of ADPKD and delay its progression, in adults with stage 1-3 chronic kidney disease (CKD) with evidence of rapidly progressing disease.

Otsuka kidney drug earns first NICE nod


NICE has released final guidance recommending Otsuka’s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic Kidney Disease (ADPKD), for use in the NHS in England and Wales. 

The drug will be issued to ADPKD adult patients with chronic kidney disease (CKD) at stages 2 or 3 at the start of treatment with evidence of rapidly progressing disease. Jinarc (tolvaptan) is the first disease-modifying treatment available on the NHS, for slowing the progression of cyst development and helping protect renal function. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches